Clinical Trials Browser

Phase 1/2 × tazemetostat × Genitourinary × Clear all

NCT03854474 2026-03-18

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT07407283 2026-02-12

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Phase 1/2 Not yet recruiting

Prostatic Neoplasms